← Back to Search

Monoclonal Antibodies

INCB050465 for Solid Tumors

Q: Are there any other investigations that have been done involving INCB050465?

<p>In 2014, the University of <a href="https://www.withpower.com/clinical-trials/minnesota">Minnesota</a>/Masonic <a href="https://www.withpower.com/clinical-trials/cancer">Cancer</a> Center was one of the first institutions to research INCB050465. So far 35 trials have been closed with 51 still in progress; many located within Chicago, <a href="https://www.withpower.com/clinical-trials/illinois">Illinois</a>.</p>

Phase 1

Waitlist Available

Research Sponsored by Incyte Corporation

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to approximately 30 months

Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and effective against cancer when used with other drugs.

Eligible Conditions

Unresectable or Metastatic Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to approximately 30 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to approximately 30 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 30 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of treatment-emergent adverse events

Secondary outcome measures

Cmax of INCB050645 when given in combination with INCMGA00012

Cmax of INCMGA00012 when given in combination with immune therapies

Cmax of epacadostat when given in combination with INCMGA00012

+7 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: Group BExperimental Treatment2 Interventions

INCMGA00012 with INCB050465.

Group II: Group AExperimental Treatment2 Interventions

INCMGA00012 with epacadostat.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Epacadostat

2018

Completed Phase 3

~1080

INCB050465

2018

Completed Phase 1

~260

Retifanlimab

2018

Completed Phase 2

~320

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor

365 Previous Clinical Trials

55,106 Total Patients Enrolled

Sadhna Shankar, MDStudy DirectorIncyte Corporation

1 Previous Clinical Trials

73 Total Patients Enrolled

Mark Cornfeld, MDStudy DirectorIncyte Corporation

1 Previous Clinical Trials

121 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many locations are conducting this research experiment?

"University of Chicago Medical Center in Chicago, Yale New Haven Hospital in New Haven and Upmc Cancercenter in Pittsburgh are 3 out of 9 sites currently offering this trial. The other 6 locations have yet to be disclosed."

Answered by AI

Is recruitment for this experiment ongoing?

"It appears that this trial is not presently accepting participants, as the last update was recorded on October 25th 2022. According to clinicaltrials.gov, however, there are currently 2431 other studies recruiting patients at the moment."

Answered by AI

Are there any other investigations that have been done involving INCB050465?

"In 2014, the University of Minnesota/Masonic Cancer Center was one of the first institutions to research INCB050465. So far 35 trials have been closed with 51 still in progress; many located within Chicago, Illinois."

Answered by AI

What is the uppermost limit of participants for this experiment?

"This clinical trial is not currently accepting participants. The study was first published on August 17th 2018 and the listing was last modified on October 25th 2022. If you are seeking other medical trials, there are 2380 cancer studies recruiting as well as 51 for INCB050465 that require volunteers."

Answered by AI

Has the FDA approved INCB050465 for public use?

"The safety of INCB050465 is rated 1 due to its being in Phase 1 trials, indicating that there exists only a limited amount of data concerning efficacy and security."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

2018. "INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03589651.